ArticleJACC. Case reports2025
Percutaneous Treatment of Multivalvular Disease Including Refractory Tricuspid Regurgitation in a Frail Elderly Patient.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis clinical vignette highlights the feasibility of a comprehensive transcatheter strategy for managing advanced multivalvular heart disease in a frail elderly patient. CASE SUMMARY: A 79-year-old woman with prior surgical aortic valve replacement, chronic atrial fibrillation, and multiple comorbidities presented with worsening heart failure. Physical examination demonstrated anasarca with signs of left and right heart failure. An echocardiogram demonstrated severe stenosis of a prior bioprosthetic aortic valve, with a valve area of 0.64 cm DISCUSSION: This case underscores the potential role of transcatheter interventions in high-risk patients, indicating that advanced age and frailty, in addition to procedural success, critically influence long-term outcomes. TAKE-HOME MESSAGE: Frailty and associated comorbidities remain pivotal challenges and require diligent postprocedural follow-up, but they are not absolute contraindications for percutaneous treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.